Browsing Tag
Kisunla
4 posts
Eli Lilly (NYSE: LLY) to acquire AtaiBeckley in $3.8bn TRD psychedelic deal
Eli Lilly (NYSE: LLY) to acquire AtaiBeckley for $6.75/share cash plus $2.50 CVR, taking the BPL-003 5-MeO-DMT depression asset to Phase 3 read in 2029.
Eli Lilly wins European approval for Kisunla, a new Alzheimer’s treatment that targets early symptomatic stages
Eli Lilly wins EU approval for Kisunla, a once-monthly Alzheimer’s therapy that slows decline and reshapes Europe’s treatment landscape.
Eli Lilly sets 2024 revenue at $45bn amid revised guidance
Eli Lilly and Company, a leading global pharmaceutical firm, has adjusted its 2024 revenue forecast to $45 billion,…
FDA approves Eli Lilly’s Kisunla for Alzheimer’s treatment
The U.S. Food and Drug Administration (FDA) has approved Kisunla (donanemab-azbt), an Alzheimer’s treatment developed by Eli Lilly…